Uveal melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
Year: 2026
Type: article
Abstract: Uveal melanoma (UM) is associated with specific challenges due to its rare incidence. Optimal management of the disease requires multidisciplinary collaboration and coordination for the diagnosis, treatment, follow-up and support of patients at all stages and clearly established referral pathways.1 All patients should have access to centres with dedicated expertise in primary and metastatic UM either nationally or through cross-border access agreements, using the potential of the existing and forthcoming European Reference Networks as outlined in Europe’s Beating Cancer Plan, the ambition of the European Union (EU) Cancer Mission and the establishment and connection of Comprehensive Cancer Care Infrastructures in the EU.
Source: ESMO Open
Authors: S. Piperno-Neumann, M. Angi, P.A. Ascierto, J.F. Baurain, M.C. Burgmans, N. Cassoux, S.E. Coupland, R. Dendale, A. Fortuna, L. Gastaud, C. Gutierrez-Miguelez, S. Heegaard, M.J. Jager, E. Kapiteijn, U. Keilholz, E. Kilic, M. Marinkovic, A. Moulin, P. Nathan, S.P. Patel, A. Pica, J.M. Piulats, B. Ryll, J.J. Sacco, W. Sauerwein, M. Schlaak, B. Stedman, A. Valente, R.M. Verdijk, C. Verhoef, O. Michielin
Institutions: Institut Curie, Fondazione IRCCS Istituto Nazionale dei Tumori, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University of Naples Federico II, Cliniques Universitaires Saint-Luc, UCLouvain, Leiden University, Leiden University Medical Center, Université Paris Cité, University of Liverpool, Liverpool University Hospitals NHS Foundation Trust, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Centre Antoine Lacassagne, Institut Català d'Oncologia, Hospital Del Mar, Copenhagen University Hospital, Rigshospitalet, Max Delbrück Center, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charité - Universitätsmedizin Berlin, Erasmus MC, Hôpital Ophtalmique Jules-Gonin, Mount Vernon Hospital, Mount Vernon Cancer Centre, University of Colorado Anschutz, Paul Scherrer Institute, Essen University Hospital, Humboldt-Universität zu Berlin, University Hospital Southampton NHS Foundation Trust, Champalimaud Foundation, Erasmus MC Cancer Institute, University Hospital of Geneva
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
Funders: American Association for Cancer Research, Amgen, Pfizer, AstraZeneca, American Society of Clinical Oncology, Regeneron Pharmaceuticals, International Society of Ocular Oncology, Society for Immunotherapy of Cancer, Les Laboratories Pierre Fabre, BeiGene, Seagen, Astellas Pharma, European Society for Medical Oncology, Sun Pharma, Fundação Champalimaud, Qbiotics
OpenAlex ID: W7147668335